• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡培他滨所致手足综合征发生的预测因素:一项回顾性观察队列研究。

Predictive factors for the development of capecitabine-induced hand-foot syndrome: a retrospective observational cohort study.

作者信息

Chantharakhit Chaichana, Sujaritvanichpong Nantapa

机构信息

Department of Internal Medicine, Division of Medical Oncology, Buddhasothorn Hospital, Chachoengsao, Thailand.

出版信息

Ann Med Surg (Lond). 2023 Nov 7;86(1):73-77. doi: 10.1097/MS9.0000000000001487. eCollection 2024 Jan.

DOI:10.1097/MS9.0000000000001487
PMID:38222767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10783358/
Abstract

BACKGROUND

Capecitabine-induced hand-foot syndrome (HFS) is a common condition that significantly affects patients' quality of life. The exact underlying mechanisms are currently not clearly understood. Therefore, the study of predictive factors for HFS is of critical importance.

MATERIALS AND METHODS

This prognostic factor research used a retrospective observational cohort as the study design. Data collected from the medical records of 205 patients treated with capecitabine between January 2019 and June 2022 were subjected to univariable and multivariable regression analysis to determine the predictive factors for the development of grade 2 and grade 3 HFS.

RESULTS

The incidence of grade 2 and grade 3 HFS was 26.8%. The independent predictive factors, such as age over 60 years (OR 4.80, 95% CI: 2.16-10.68, <0.001), capecitabine dose greater than 3000 mg/day (OR 2.47, 95% CI: 1.09-5.59, =0.030), and the number of cycles five or more in the total capecitabine regimen (OR 2.94, 95% CI: 1.29-6.71, =0.01), were significantly associated with the development of grade 2 and grade 3 HFS.

CONCLUSIONS

Independent predictive factors for the development of grade 2 and grade 3 HFS in patients treated with capecitabine include age over 60, capecitabine dose greater than 3000 mg/day, and patients who plan to undergo five or more cycles in the total capecitabine regimen. This knowledge can be valuable for guiding clinical monitoring and follow-up of patients.

摘要

背景

卡培他滨引起的手足综合征(HFS)是一种常见病症,严重影响患者的生活质量。目前尚不清楚其确切的潜在机制。因此,研究HFS的预测因素至关重要。

材料与方法

本预后因素研究采用回顾性观察队列作为研究设计。收集了2019年1月至2022年6月期间接受卡培他滨治疗的205例患者的病历数据,进行单变量和多变量回归分析,以确定2级和3级HFS发生的预测因素。

结果

2级和3级HFS的发生率为26.8%。独立预测因素,如年龄超过60岁(OR 4.80,95%CI:2.16 - 10.68,<0.001)、卡培他滨剂量大于3000 mg/天(OR 2.47,95%CI:1.09 - 5.59,=0.030)以及卡培他滨总疗程中循环次数为五次或更多(OR 2.94,95%CI:1.29 - 6.71,=0.01),与2级和3级HFS的发生显著相关。

结论

接受卡培他滨治疗的患者发生2级和3级HFS的独立预测因素包括年龄超过60岁、卡培他滨剂量大于3000 mg/天以及卡培他滨总疗程计划进行五次或更多循环的患者。这些知识对于指导患者的临床监测和随访可能具有重要价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5993/10783358/83cd42ffdbc2/ms9-86-073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5993/10783358/83cd42ffdbc2/ms9-86-073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5993/10783358/83cd42ffdbc2/ms9-86-073-g001.jpg

相似文献

1
Predictive factors for the development of capecitabine-induced hand-foot syndrome: a retrospective observational cohort study.卡培他滨所致手足综合征发生的预测因素:一项回顾性观察队列研究。
Ann Med Surg (Lond). 2023 Nov 7;86(1):73-77. doi: 10.1097/MS9.0000000000001487. eCollection 2024 Jan.
2
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.手足综合征及其预防药物——吡哆醇的预测因子:卡培他滨致手足综合征的随机临床试验。
JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.
3
Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.卡培他滨治疗的癌症患者手足综合征:马来西亚癌症中心对其发生率、影响及相关危险因素的研究。
Support Care Cancer. 2024 May 14;32(6):345. doi: 10.1007/s00520-024-08490-7.
4
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).卡培他滨治疗患者中双氯芬酸局部预防手足综合征的随机双盲、安慰剂对照研究(D-TORCH 研究)。
Trials. 2022 May 19;23(1):420. doi: 10.1186/s13063-022-06353-2.
5
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.吡哆醇预防卡培他滨治疗相关性手足综合征的疗效:一项随机、双盲、安慰剂对照研究的结果。
J Clin Oncol. 2010 Aug 20;28(24):3824-9. doi: 10.1200/JCO.2010.29.1807. Epub 2010 Jul 12.
6
SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.COX-2/PGES/EP 信号通路中的 SNPs 与卡培他滨引起的严重手足综合征的风险相关。
Cancer Chemother Pharmacol. 2020 Apr;85(4):785-792. doi: 10.1007/s00280-020-04053-9. Epub 2020 Mar 19.
7
Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.包含强化预防措施的结构化教学模块对降低卡培他滨所致手足综合征发生率的影响:一项前瞻性随机III期研究的结果
Oncologist. 2020 Dec;25(12):e1886-e1892. doi: 10.1634/theoncologist.2020-0698. Epub 2020 Sep 4.
8
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.卡培他滨所致手足综合征:超越 DPYD 的药物遗传学研究。
Biomed Pharmacother. 2023 Mar;159:114232. doi: 10.1016/j.biopha.2023.114232. Epub 2023 Jan 9.
9
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.卡培他滨相关性手足综合征的预防性治疗:AIO 生活质量工作组的一项多中心 III 期随机试验,比较 MAPISAL 乳膏和尿素乳膏。
J Clin Oncol. 2015 Aug 1;33(22):2444-9. doi: 10.1200/JCO.2014.60.4587. Epub 2015 Jun 29.
10
Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.卡培他滨作为辅助化疗用于结直肠癌患者时手足综合征的依从性和有效管理。
Yonsei Med J. 2009 Dec 31;50(6):796-802. doi: 10.3349/ymj.2009.50.6.796. Epub 2009 Dec 18.

引用本文的文献

1
Identification of metabolites associated with capecitabine‑induced hand‑foot syndrome using untargeted metabolomics in patients with cancer.利用非靶向代谢组学鉴定癌症患者中与卡培他滨诱导的手足综合征相关的代谢物。
Mol Med Rep. 2025 Jul;32(1). doi: 10.3892/mmr.2025.13568. Epub 2025 May 16.
2
Discoloration and Dilemma: A Case Report of Hand-Foot Syndrome Associated With Capecitabine Use.色素沉着与困境:一例与卡培他滨使用相关的手足综合征病例报告
Cureus. 2024 Jul 22;16(7):e65151. doi: 10.7759/cureus.65151. eCollection 2024 Jul.

本文引用的文献

1
Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study.卡培他滨致手足综合征的危险因素:单中心回顾性研究。
Oncology. 2023;101(7):407-414. doi: 10.1159/000529851. Epub 2023 Apr 19.
2
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.卡培他滨所致手足综合征:超越 DPYD 的药物遗传学研究。
Biomed Pharmacother. 2023 Mar;159:114232. doi: 10.1016/j.biopha.2023.114232. Epub 2023 Jan 9.
3
Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation.
卡培他滨引起的手足综合征:发病率、危险因素及皮肤评估的作用
Ecancermedicalscience. 2022 May 16;16:1390. doi: 10.3332/ecancer.2022.1390. eCollection 2022.
4
STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery.STROCSS 2021:加强外科学队列研究、横断面研究和病例对照研究报告规范。
Int J Surg. 2021 Dec;96:106165. doi: 10.1016/j.ijsu.2021.106165. Epub 2021 Nov 11.
5
Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance.卡培他滨代谢产物 5'-脱氧-5-氟胞苷的代谢转化与肌酐清除率的相关性。
In Vivo. 2020 Nov-Dec;34(6):3539-3544. doi: 10.21873/invivo.12196.
6
SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.COX-2/PGES/EP 信号通路中的 SNPs 与卡培他滨引起的严重手足综合征的风险相关。
Cancer Chemother Pharmacol. 2020 Apr;85(4):785-792. doi: 10.1007/s00280-020-04053-9. Epub 2020 Mar 19.
7
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.手足综合征及其预防药物——吡哆醇的预测因子:卡培他滨致手足综合征的随机临床试验。
JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269.
8
Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.S-1 对比卡培他滨用于转移性结直肠癌一线治疗的随机 III 期临床试验:荷兰结直肠癌研究组 SALTO 研究。
Ann Oncol. 2017 Jun 1;28(6):1288-1293. doi: 10.1093/annonc/mdx122.
9
The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome.角质形成细胞在卡培他滨诱发的手足综合征中的作用。
Environ Toxicol Pharmacol. 2017 Jan;49:81-88. doi: 10.1016/j.etap.2016.12.001. Epub 2016 Dec 5.
10
Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.探索卡培他滨治疗期间5-氟尿嘧啶核苷酸的细胞内药代动力学。
Br J Clin Pharmacol. 2016 May;81(5):949-57. doi: 10.1111/bcp.12877. Epub 2016 Mar 2.